Increased mortality in ankylosing spondylitis is related to disease activity.
about
Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritisSafe prescribing of non-steroidal anti-inflammatory drugs in patients with osteoarthritis--an expert consensus addressing benefits as well as gastrointestinal and cardiovascular risksCardiovascular Comorbidity in Inflammatory Rheumatological Conditions.Genome-wide association study identifies candidate genes for piglet splay leg syndrome in different populations.The epidemiology of back pain, axial spondyloarthritis and HLA-B27 in the United StatesIncreasing proportion of female patients with ankylosing spondylitis: a population-based study of trends in the incidence and prevalence of ASCardiovascular risk management in patients with active ankylosing spondylitis: a detailed evaluation.Time trends in incidence, clinical features, and cardiovascular disease in ankylosing spondylitis over three decades: a population-based study.The assessment of the spondyloarthritis international society concept and criteria for the classification of axial spondyloarthritis and peripheral spondyloarthritis: A critical appraisal for the pediatric rheumatologist.Clinical Assessment and Management of Spondyloarthritides in the Middle East: A Multinational Investigation.Management and evaluation of extra-articular manifestations in spondyloarthritisAlterations of bone mineral density, bone microarchitecture and strength in patients with ankylosing spondylitis: a cross-sectional study using high-resolution peripheral quantitative computerized tomography and finite element analysis.Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditionsCardiorespiratory fitness and cardiovascular risk in patients with ankylosing spondylitis: a cross-sectional comparative studyAnkylosing Spondylitis: A rheumatology clinic experience.The effect of physical activity and motivation on function in ankylosing spondylitis: a cohort study.A multilectin affinity approach for comparative glycoprotein profiling of rheumatoid arthritis and spondyloarthropathy.Cardiovascular and cerebrovascular diseases in ankylosing spondylitis: current insights.Biologic therapies for spondyloarthritis: what is new?The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain.Epidemiology of spondyloarthritis: a review.Rehabilitation and surgical management of ankylosing spondylitis.Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?Active axial spondyloarthritis: potential role of certolizumab pegol.Axial spondyloarthritis: the heart of the matter.Posttraumatic stress disorder and correlates of disease activity among veterans with ankylosing spondylitis.Improving the Management of Psoriatic Arthritis and Axial Spondyloarthritis: Roundtable Discussions with Healthcare Professionals and Patients.Mortality in patients with ankylosing spondylitis in Argentina.An update on the use of tumor necrosis factor alpha inhibitors in the treatment of ankylosing spondylitis.Cardiovascular adverse events by non-steroidal anti-inflammatory drugs: when the benefits outweigh the risks.CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: results after 5-year follow-up.Treat to Target in Axial Spondyloarthritis: What Are the Issues?Cervical Spinal Fracture and Other Diagnoses Associated With Mortality in Hospitalized Ankylosing Spondylitis Patients.The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis.Cardiovascular risk profiles in a hospital-based population of patients with psoriatic arthritis and ankylosing spondylitis: a cross-sectional study.Mortality in ankylosing spondylitis: results from a nationwide population-based study.The risk of pneumococcal infections after immunization with pneumococcal conjugate vaccine compared to non-vaccinated inflammatory arthritis patients.Axial spondyloarthritis: is there a treatment of choice?Assessment of SpondyloArthritis International Society criteria for axial spondyloarthritis in chronic back pain patients with a high prevalence of HLA-B27.Modifiable cardiovascular risk factors in patients with ankylosing spondylitis.
P2860
Q26852081-3120B172-DA22-44A9-BE5B-3CDEBCCBE3E4Q30629677-74B4A21A-4D54-4EEE-8EA8-15EFDA966B72Q33582869-15390CAD-921F-448D-8C32-D0574ECD76EFQ33876945-FC29FD3D-E128-4C1D-B761-F317FF828D7EQ34004546-298C2F42-E507-4413-9001-BEF194A09B5EQ34707552-30FA9C63-D2F5-4287-82DE-345DBF24CF7AQ35496549-7BC928F3-BAE5-42FB-A0BA-C0292715BB0EQ35997346-110A5FCC-AE39-4D44-BD56-37BC621041C4Q36112605-05836319-D115-4318-8950-A07A6F180EE9Q36419077-A8DD9687-516B-481A-9F48-558348BA36D9Q36439889-A49101F4-6045-4686-B2F7-A8500D9D1BBDQ36477404-35E5E964-E118-47DD-B243-64EC155AC997Q36746012-208BD129-8ECE-4CA2-A409-2B2BD2996295Q36746588-C8D5937A-EB52-4ED8-95AA-FA0449E3E247Q36876400-096860D7-BBBF-48A4-BF00-681954D333CFQ36938185-3882AA96-1811-4813-AD2B-985F6EB97B53Q37356331-6E7AB262-F96D-486B-ABB4-90F8888AAC41Q38025994-253317C9-A573-499C-98C3-08D567AD9A9BQ38031436-C77CC662-80D6-44FB-9482-2A7E72130D23Q38086926-E4B8CC78-62E1-4F25-9FB8-E4CCC619A15BQ38124275-7E66B2B3-51CE-4BC5-A870-B6DF71D5A7A1Q38129350-CFAC8703-E736-4677-8D41-3AFA92AD0D9BQ38185646-E8AF7946-0021-42A7-BCED-E7FBC96153E5Q38194547-199C31B4-6834-46E5-8AC9-42FD3B22E6BDQ38469239-840D048B-0FD9-41E5-B69E-CFA44E9EDC79Q38608792-549FD9FB-D414-43B6-BE9E-96630D428315Q38672570-2AA615AF-2528-4CC6-99D8-BB97455DFE14Q38885761-7CE767FF-0486-4D6C-A293-AAD947EEDC0DQ38914839-A731545D-D3FF-41C5-8E3F-F0916D5D870BQ38941017-C37C218E-DD83-4971-A7E7-3DB305AA631DQ39026806-D4054B26-0525-4044-90BA-0AF817E614FAQ39225782-1AF68BF5-1582-4958-9C57-3839502F6DF7Q39782986-A4C17588-CD13-4CE7-B77E-DA6B4491898DQ39838349-F0140964-C4D9-4CC7-B735-0F57CB683F27Q40455996-F1A51596-1757-4784-B2AF-6431C9CC2081Q41016710-4735DA86-1D65-42D4-AC47-CE53FD1EC110Q41471703-9E3AF2FC-33B1-4FB9-9EAA-80CABF861E26Q42013856-731FC303-8997-43C2-90AC-0442B2066F86Q43759230-A4E4D7F2-6703-49B6-A83F-79EFF943F8FCQ43986221-88B09CEE-8DFC-437F-B8AF-B1AC9B0194D8
P2860
Increased mortality in ankylosing spondylitis is related to disease activity.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Increased mortality in ankylosing spondylitis is related to disease activity.
@ast
Increased mortality in ankylosing spondylitis is related to disease activity.
@en
Increased mortality in ankylosing spondylitis is related to disease activity.
@nl
type
label
Increased mortality in ankylosing spondylitis is related to disease activity.
@ast
Increased mortality in ankylosing spondylitis is related to disease activity.
@en
Increased mortality in ankylosing spondylitis is related to disease activity.
@nl
prefLabel
Increased mortality in ankylosing spondylitis is related to disease activity.
@ast
Increased mortality in ankylosing spondylitis is related to disease activity.
@en
Increased mortality in ankylosing spondylitis is related to disease activity.
@nl
P356
P1476
Increased mortality in ankylosing spondylitis is related to disease activity
@en
P2093
Gunnstein Bakland
Jan Tore Gran
P304
P356
10.1136/ARD.2011.151191
P407
P577
2011-07-21T00:00:00Z